MDT-AP-2892
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 16
- sex
- M
- new_clusters
- C5
- umap1_2d
- 3.274276929
- umap2_2d
- 3.710657404
- umap1_3d
- 0.845957578
- umap2_3d
- -0.001850682
- umap3_3d
- -0.134183094
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.570
- ALLOGRAFT_REJECTION+0.530
- TNFA_SIGNALING_VIA_NFKB+0.520
- ANGIOGENESIS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- IL6_JAK_STAT3_SIGNALING+0.470
- INTERFERON_GAMMA_RESPONSE+0.470
- COMPLEMENT+0.440
- COAGULATION+0.430
- KRAS_SIGNALING_DN+0.420
Top 10 suppressed
- MYC_TARGETS_V1-0.580
- MYC_TARGETS_V2-0.560
- DNA_REPAIR-0.520
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.470
- MITOTIC_SPINDLE-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.460
- OXIDATIVE_PHOSPHORYLATION-0.420
- PROTEIN_SECRETION-0.410
- WNT_BETA_CATENIN_SIGNALING-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2638 | Med | Medulloblastoma | 0.959 |
| 2 | SRR1319539 | GTEX | — | 0.957 |
| 3 | SRR1442666 | GTEX | — | 0.953 |
| 4 | ERR2598337 | fetal | fetal | 0.952 |
| 5 | BS_3H71BH6Q | Ganglioglioma | — | 0.943 |
| 6 | sclcA055A_S52.txt | — | cohortMD2 | 0.941 |
| 7 | sclc0617_S65.txt | — | cohortMD2 | 0.939 |
| 8 | SRR1397906 | GTEX | — | 0.936 |
| 9 | SRR601787 | GTEX | — | 0.935 |
| 10 | BS_W97QQYKQ | Ganglioglioma | — | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |